Ryan D. Maynard, CHIEF FINANCIAL OFFICER at Cara Therapeutics, Inc. (CARA), sold 5,488 shares at $0.53 ($3K) on 2023-02-08, disclosed to the SEC on 2024-02-12.
Scheduled sale ($3k) by CHIEF FINANCIAL OFFICER under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| RIGL | SELL | 2017-11-07 | $390K | — | Filing → |
| RIGL | SELL | 2012-09-14 | $249K | — | Filing → |
| RIGL | SELL | 2012-09-14 | $249K | — | Filing → |